Live·Verified funding discovery · 2026.2
874 grants · 19 open · 435 companies · 2640 concepts874 / 19 / 435 / 2640
△COMPANIESCompanies rated · 435 (no change)△PROJECTSProjects rated · 70 (no change)△CATALOGUE874 grants in catalogue · 19 open right now•POWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CA△COMPANIESCompanies rated · 435 (no change)△PROJECTSProjects rated · 70 (no change)△CATALOGUE874 grants in catalogue · 19 open right now•POWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CA
← ← Back to projectsDiagnostics & Biomarkers →

CHANGS

Diagnostics & BiomarkersLast rated 5/25/2026UniversityCanonical source ↗

CHANGS is a newly announced 2025 Chulalongkorn University-BGI collaboration in Thailand focused on healthy aging, using omics and AI-based bioinformatics to analyze elderly health, collect volunteer samples and clinical data, and reportedly build outputs such as multi-omic aging measures and organ-aging models. The evidence supports that the project exists and has institutional backing, but not that it has yet produced validated biomarkers, intervention results, or clinical utility.

Source coverage

17 sources searched, 222 evidence rows (170 with full text)
Team project0Project page1Project page crawl6PubMed0Semantic Scholar0OpenAlex0arXiv0bioRxiv0Web search23News16YouTube10Wikipedia39GitHub1Author publications0Organization records0Patents (project-held)10Patents (field corridor)49
Non-commercial entity

This project is run by a university research project. Any funding here takes the form of a grant, donation, or public contract — not equity. There is no financial return expected.CHANGS is a Chulalongkorn University-led research collaboration, so the project is best categorized as a university-affiliated initiative.

Scientific

Mechanism and evidence quality

38.5

Breakthrough

How much success could unlock

36.5

Investor

Deal-quality signals

38.4

Overall

Weighted composite

37.9

Where this project sits

Positioned against every public project across all sections

0255075100048121620LIFESPAN GAIN (YEARS, ESTIMATED)OVERALL SCOREmax in DB: 15 yrCHANGS
BioreplacementBioinformationDrug & Molecule DiscoveryGenetic & Cellular TherapiesAging Biology ResearchDiagnostics & BiomarkersBrain & Cognitive LongevityResearch & Funding Infrastructure
Inner ring · capital to breakeven  ·  Outer ring · best-case upside multiple

Comprehensive brief

Hypothesis

Deep multi-omic profiling of older adults in Thailand, combined with AI-driven analysis, can generate useful models of human aging and identify biomarkers or intervention-response signals that improve understanding of healthy aging and eventually inform diagnostics, prevention, and care.

Mechanism

The proposed mechanism is observational and computational rather than therapeutic: CHANGS plans to combine blood and tissue multi-omics, single-cell genomics, spatial transcriptomics, and bioinformatics/ML to characterize aging states, estimate organ aging, and compare signatures across people and possibly across anti-aging interventions. The project is positioned around extracting aging-related patterns from high-dimensional human data, not around a demonstrated causal intervention.

Approach

The clearest evidence-backed approach is a Chulalongkorn-BGI partnership in which Chulalongkorn collects volunteer samples and clinical data from Thailand’s elderly population, BGI provides omics and analysis technology support, and both sides jointly analyze the data. Reported planned applications include aging measurement from blood and tissues, AI-based organ-aging models, machine-learning integration of multi-omics, and evaluation of anti-aging interventions in human populations; a linked joint international PhD track suggests added talent-building and research-program infrastructure.

Status

Early-stage and pre-results. Multiple 2025 institutional and corporate announcements indicate the collaboration was formally launched on January 31, 2025, but the provided evidence contains no cohort size, protocol, endpoints, validation study, published dataset, biomarker performance, or peer-reviewed outcome data.

Success criteria

Near-term success would require more than partnership announcements: a defined cohort in Thailand, reproducible sample/data pipelines, published methods, and at least one validated aging-related model or biomarker with measurable predictive value beyond standard clinical variables. Stronger success would mean external validation, credible evidence that the models track meaningful health outcomes or intervention response, and clear evidence that the Thailand-specific dataset adds signal rather than only producing a local data repository.

Near-term impact (1-3 yrs)

If the central claim is validated in the next 1-3 years, CHANGS could enable practical aging-measurement workflows for Thai elderly cohorts, stratify participants by biological or organ-specific aging patterns, and make human-population evaluation of anti-aging interventions more data-driven. It could also produce reusable multi-omic datasets, analysis pipelines, and trained researchers for aging studies in Thailand, but claims about diagnostics or treatment impact would still need separate validation.

Future horizons (5-20 yrs)

If CHANGS succeeds over 5-20 years, it could help establish population-specific, multi-omic aging maps in Southeast Asia; support a broader class of organ-aging models, intervention-response biomarkers, and longitudinal preventive-health tools; and normalize combining clinical phenotypes with single-cell and spatial omics in aging research. The larger upside is not a single therapy but a new regional evidence base for computational geroscience, though this depends on proving that these complex models generalize, remain interpretable enough for use, and improve decisions in real populations.

Breakthrough thesis

CHANGS could become a rare large-scale human aging program in Southeast Asia that links rich clinical data with single-cell, spatial, and multi-omic profiling, producing regionally grounded aging models rather than importing clocks and assumptions from other populations. If those models prove robust, the project could materially improve how aging is measured, how interventions are evaluated, and how elderly care strategies are tailored in Thailand.

Failure thesis

The current evidence is mostly promotional and institution-authored, so the main failure mode is that CHANGS remains a collaboration and training brand without generating validated outputs. Multi-omic aging projects are vulnerable to overpromising, high cost, small or biased cohorts, weak causal inference, and models that fit data but do not generalize clinically; without transparent methods and external validation, CHANGS could produce impressive-sounding AI/omics artifacts with limited real-world value.

Risk of failure

Technical84

CHANGS is proposing a technically ambitious stack: multi-omic profiling of human blood and tissues, single-cell genomics, spatial transcriptomics, and AI-based organ-aging models. But the project-specific evidence is still launch and recruitment material rather than any demonstrated model performance, assay reproducibility, or validated biomarker output. The broader field has active IP around organ-aging biomarkers and biological-age estimation, which suggests the concept is scientifically plausible but also technically difficult and far from solved.

Translational81

The project is framed around measuring aging and evaluating interventions in human populations, but the cited evidence does not show prospective validation, clinical endpoints, or proof that any inferred aging signal improves real decisions in care. Current evidence shows an observational research collaboration and a PhD pipeline, not a clinically useful product. That makes the jump from rich omics data to actionable human translation a major risk.

Regulatory / jurisdictional67

This is not yet a therapeutic program, so classic drug-approval risk is lower than for an intervention company. However, it does involve human clinical data and biosamples across a Thailand-China collaboration, which creates consent, data-transfer, and institutional oversight burden. BGI also sits inside a geopolitically sensitive biotech context, which raises partnership and investor-perception risk even if CHANGS itself is research-stage.

Competitive dynamics72

CHANGS is entering a crowded and fast-moving area. Its own materials target aging measurement, organ-aging models, and multi-omics integration, while the broader field already shows active IP around organ-aging biomarkers, biological-age clocks, and spatial transcriptomics platforms. Without near-term differentiated validation in Thai cohorts, the project could be overtaken by better-funded groups or reduced to a local data-generation effort rather than a category-defining platform.

Team / operational58

There is real institutional structure here: the collaboration was formally launched, roles are divided between Chulalongkorn for sample and clinical-data collection and BGI for technology and analysis, and the joint PhD program adds talent pipeline support. That lowers pure organizational risk. But execution evidence is still thin: no cited cohort size, milestones, protocols, or early deliverables, so operational confidence should remain only moderate.

Funding / capital69

Human multi-omics programs that include single-cell and spatial methods are capital-intensive, especially if they are meant to generate longitudinally useful aging models. The evidence suggests some nontrivial institutional support, including university and BGI backing plus funded PhD tracks, which helps. Still, there is no cited evidence of a dedicated long-duration program budget, large grant, or financing plan sized to sustain cohort recruitment, omics generation, and downstream validation.

Scientific panel

Mechanism plausibility62

The proposed mechanism is scientifically plausible as an observational/computational aging study: CHANGS plans to combine omics technologies with AI-based bioinformatics to analyze elderly health in Thailand, and the PhD program lists multi-omic profiling, organ-aging models, and ML integration as research areas. However, the project evidence does not show a causal biological mechanism, validated biomarkers, or demonstrated links from model outputs to health outcomes or interventions.

Evidence base38

The evidence base supports project existence, institutional backing, and a defined general approach: Chulalongkorn and BGI launched CHANGS, with Chulalongkorn collecting clinical data and samples and BGI supporting technology and analysis. Field-context evidence indicates aging biomarkers, biological-age models, single-cell, spatial transcriptomics, and BGI genomics infrastructure are active domains, but this is indirect and low-weight. There is no project cohort size, protocol, dataset, model performance, validation paper, or peer-reviewed CHANGS result.

Methodological rigor18

The project-specific evidence describes broad objectives and technologies but gives no study design details, inclusion criteria, longitudinal plan, controls, endpoint definitions, statistical power, preregistration, data governance, or validation split. The planned use of clinical data, volunteer samples, multi-omics, and ML is not enough to infer rigorous execution.

Reproducibility8

No CHANGS-specific replication evidence is provided. The record contains launch announcements and training-program descriptions, but no published methods, open dataset, code, independent replication, or replication of the team’s own aging-model outputs.

Novelty55

CHANGS is not novel at the level of using omics, AI, biological-age models, or intervention-response profiling; those are established themes. Its stronger novelty is contextual: a Thailand-focused elderly cohort under a Chulalongkorn-BGI collaboration, with stated integration of single-cell genomics, spatial transcriptomics, bioinformatics, AI healthcare, and aging/regenerative-medicine training. That is regionally distinctive but not yet a demonstrated scientific breakthrough.

Falsifiability42

The central claim could be falsified if CHANGS-derived multi-omic or organ-aging models fail to predict aging-related outcomes, intervention response, or clinically meaningful phenotypes beyond standard variables. But the current evidence does not state concrete hypotheses, endpoints, success thresholds, validation cohorts, or timelines, so falsifiability is only implicit in the planned modeling work.

Breakthrough panel

Mechanism novelty35

CHANGS combines omics, AI bioinformatics, single-cell/spatial methods, and organ-aging models for elderly Thai cohorts, but this is mainly an application of established aging-clock and multi-omic profiling ideas rather than a new biological mechanism or therapeutic modality. The evidence describes observational measurement and modeling, not a new causal aging intervention.

Effect size+0.8 yr lifespan★20

The plausible effect size is modest because CHANGS is an indirect discovery and measurement platform, not a proven intervention. If successful, it may improve cohort stratification or help identify intervention-response biomarkers, but the evidence contains no validated biomarker performance, treatment data, or demonstrated healthspan gain. I anchor the lifespan/healthspan estimate at the low end of the platform range.

Cross-domain impact34

Near-term spillover could help genomics, bioinformatics training, regenerative-medicine research, and elderly-health analytics, especially through the PhD program and proposed multi-omics integration. However, the evidence is still mostly announcements and training/program descriptions, so current cross-domain impact is potential rather than demonstrated capability.

Future opening potential55

If CHANGS produces a well-characterized Thai elderly cohort with reproducible omics pipelines, it could open useful population-specific aging maps and organ-aging models for Southeast Asia. The upside is real but conditional: existing evidence shows a collaboration and intended research areas, not scale, protocols, longitudinal outcomes, or external validation.

Time horizon~3 yr★52

A first demonstrable result, such as cohort data, a preliminary multi-omic aging measure, or an organ-aging model, could plausibly appear within about three years because the collaboration was formalized in January 2025 and the project is built around data collection and analysis rather than drug development. Clinically meaningful validation would take longer.

Paradigm shift signal25

Even if successful, CHANGS would more likely extend current multi-omic aging research into an underrepresented population than overturn mainstream assumptions. The evidence supports institutional backing and ambitious modeling goals, but not a result that would force a major rethink of aging biology or clinical care.

Investor panel

Most attractive
Team execution capacity (60)

Execution capacity is the strongest investor dimension: Chulalongkorn and BGI formally launched the collaboration, with Chula collecting clinical data/samples and BGI providing technology and analysis support. BGI's broader page claims a large genomics platform, many published papers, and high-throughput sequencing/clinical testing scale. Still, there is no CHANGS cohort size, protocol, dataset, publication, or delivered model yet.

Most concerning
Founder skin in the game (18)

The evidence shows institutional participation and public signing, but no founder/PI personal capital, salary sacrifice, equity exposure, or unusually high personal career risk. Public reputation is modestly at stake because named institutions and BGI leadership are attached, but that is not the same as founder skin in game.

Addressable market$10B★55

The target problem, healthier aging and elderly-care analytics, is broad, and CHANGS explicitly aims at Thailand's elderly population with possible worldwide diagnostic/treatment benefit. However, the fetched evidence gives no market-size source, payer evidence, or product definition; TAM is therefore estimated with low confidence around a potential aging-biomarker and preventive-health analytics market rather than a proven commercial category.

Defensibility38

Potential defensibility would come from a Thailand-specific elderly cohort, linked clinical samples, multi-omic data, and BGI's sequencing/bioinformatics infrastructure. The evidence does not show exclusive data rights, CHANGS-specific patents, validated models, proprietary algorithms, or locked-in clinical channels, so defensibility is plausible but unproven.

Team execution capacity60

Execution capacity is the strongest investor dimension: Chulalongkorn and BGI formally launched the collaboration, with Chula collecting clinical data/samples and BGI providing technology and analysis support. BGI's broader page claims a large genomics platform, many published papers, and high-throughput sequencing/clinical testing scale. Still, there is no CHANGS cohort size, protocol, dataset, publication, or delivered model yet.

Founder skin in the game18

The evidence shows institutional participation and public signing, but no founder/PI personal capital, salary sacrifice, equity exposure, or unusually high personal career risk. Public reputation is modestly at stake because named institutions and BGI leadership are attached, but that is not the same as founder skin in game.

Customer validation signal24

There is evidence of volunteer sample/data collection plans and a PhD recruitment program, but not of paying customers, pharma partnerships, LOIs, clinical adoption, patient enrollment numbers, regulatory designations, or end-user purchasing demand. The project appears research-driven rather than customer-validated.

Burn to breakeven$35M★42

CHANGS is closer to an AI/bioinformatics and multi-omics platform than a therapeutic biotech program, so the estimate uses the provided AI drug discovery/bioinformatics platform benchmark, but with upward pressure from sample collection, single-cell/spatial omics, data curation, and validation. Estimated capital to self-sustaining operations is $35M, assuming grants, institutional support, and eventual analytics/service revenue; evidence does not show current funding or burn.

Time to value4 yr★36

The collaboration was formalized on January 31, 2025 and is pre-results. A first research readout or dataset could arrive within several years, but revenue, licensing, or clinical utility would likely require cohort completion and external validation. I estimate 48 months to a meaningful readout or early partnership value, not to mature clinical revenue.

Regulatory pathway clarity32

As currently described, CHANGS is observational/computational research. If outputs become diagnostics or clinical decision tools, they would need validation and regulatory framing, but the evidence gives no intended indication, assay type, jurisdictional route, endpoints, or precedent package. Field patents show biological-age and organ-aging biomarkers exist as a category, but not a clear path for CHANGS.

Competitive freedom34

CHANGS may differentiate through a Thai elderly population dataset and BGI/Chula infrastructure, but the field is crowded. The fetched field evidence includes many patents around biological-age prediction, aging biomarkers, organ-aging biomarkers, methylation/proteomic/microbiome clocks, single-cell genomics, and spatial transcriptomics, implying limited freedom unless CHANGS generates uniquely valuable population-specific data.

Asymmetric upside10×★50

Best case is meaningful: a validated Southeast Asian aging dataset and organ-aging model stack could support diagnostics, intervention evaluation, and broader preventive-health infrastructure. But this is not a therapy, and there is no evidence yet of validated biomarkers, clinical utility, or commercialization rights. I use a 10x upside anchor, more like research tools/services than a breakout biotech platform.

Exit landscape25

The fetched evidence contains many patents and field examples, but no verified M&A, licensing, or option comparables for aging clocks, multi-omics aging platforms, or CHANGS-like population genomics programs. Exit landscape is therefore weakly evidenced; a strategic path may exist through diagnostics, research tools, or data partnerships, but no deal evidence was provided.

Cost to commercialize$25M★40

Commercializing a validated aging-measurement workflow would likely be less capital-intensive than a therapeutic, but multi-omic cohort generation, single-cell/spatial profiling, model validation, quality systems, and clinical studies are expensive. I estimate $25M to first commercial product, using the lower-middle of the AI/bioinformatics platform benchmark plus wet-lab validation burden.

Authors

No authors resolved yet.

Scientific theories

Longitudinal omics cohort mechanism discoveryPrimarymanual entrymedium

A closely monitored longevity cohort combined with high-throughput omic measurements should reveal molecular patterns that causally distinguish healthier or longer-lived individuals from typical aging trajectories. The implied mechanism is that dense longitudinal phenotyping plus omics can identify biological pathways, biomarkers, or regulatory networks associated with slowed aging, preserved healthspan, or protection from age-related disease. Testable predictions include that omic signatures measured in the cohort will correlate with longevity and healthspan outcomes, predict future age-related disease risk, and identify candidate mechanisms that can be validated experimentally or in independent cohorts.

Popperian evaluation
Premise plausibility7.0/10

The core premise is biologically credible: longitudinal phenotyping can capture variation in aging trajectories, and omics can reflect molecular pathways, biomarkers, and regulatory states relevant to healthspan and disease risk. The weaker part is the causal leap from cohort-associated omic patterns to mechanisms that distinguish slower aging from ordinary correlates or consequences of health status.

Supporting
  • Dense longitudinal phenotyping is explicitly proposed to track aging trajectories, healthspan, and disease emergence over time.
  • High-throughput omics plausibly measures molecular variation related to biomarkers, pathways, and regulatory networks.
  • The theory distinguishes association-based discovery from later validation in experiments or independent cohorts.
Counter
  • The evidence context provides no publications or empirical results supporting this specific cohort design.
  • The assumption that observed omic differences include causal or mechanistically informative signals is marked low confidence.
  • Confounding, reverse causation, survivorship effects, and lifestyle or clinical differences could generate omic patterns without revealing aging mechanisms.
Explanatory power5.0/10

The theory offers a plausible discovery framework for explaining molecular differences between healthier and less healthy aging trajectories, but it does not yet explain observed evidence better than alternatives. Its explanatory power is limited because the provided context contains predictions and assumptions rather than demonstrated findings, and correlation-based omics can often be explained by non-causal biomarkers, disease burden, environment, or cohort structure.

Supporting
  • The theory can account for why healthier or longer-lived individuals may show distinct molecular signatures over time.
  • It proposes links among omic signatures, longevity outcomes, healthspan outcomes, and future age-related disease risk.
  • It includes a pathway from observational signatures to candidate mechanisms for later validation.
Counter
  • No observed cohort results are provided to show that the theory explains data better than standard epidemiologic or biomarker models.
  • Alternative explanations such as confounding, downstream disease effects, medication exposure, diet, exercise, ancestry, or socioeconomic factors could explain omic differences.
  • The mechanism remains broad: many pathways, biomarkers, or networks could fit the theory after the fact.
Falsifiability7.0/10

The theory makes several testable predictions: omic signatures should correlate with longevity and healthspan, predict future age-related disease risk, and nominate mechanisms that validate experimentally or in independent cohorts. It could be weakened or falsified if well-powered longitudinal analyses fail to find reproducible predictive signatures or if nominated mechanisms fail validation. However, the theory is broad enough that negative findings in one omic layer, cohort, or disease endpoint might be dismissed rather than treated as decisive.

Supporting
  • Predictions include measurable correlations with longevity outcomes.
  • Predictions include measurable correlations with healthspan outcomes.
  • Predictions include prospective prediction of future age-related disease risk.
  • Predictions include external or experimental validation of candidate mechanisms.
Counter
  • The theory does not specify effect sizes, time windows, omic modalities, statistical thresholds, or minimum validation criteria.
  • Because it allows many possible biomarkers, pathways, and regulatory networks, failed candidates may not strongly falsify the broader claim.
  • Correlation-based predictions are easier to test than the stronger causal mechanism claim.
Ambition8.0/10

The theory targets a major unsolved aging problem: identifying molecular mechanisms that distinguish healthier or longer-lived individuals from typical aging trajectories. Its ambition is high because it aims to move from dense human longitudinal data to mechanistic discovery and disease-risk prediction. It is less than maximally ambitious because the mechanism is not highly distinctive; it is a broad systems-biology discovery strategy rather than a sharply specified causal aging theory.

Supporting
  • The theory addresses longevity, healthspan, slowed aging, and protection from age-related disease.
  • It proposes integrating dense longitudinal phenotyping with high-throughput omics.
  • It aims to identify pathways, biomarkers, or regulatory networks with potential experimental or independent-cohort validation.
Counter
  • The mechanism is broad and platform-driven rather than a specific novel causal hypothesis.
  • Discovery of associations and candidate biomarkers is less bold than directly specifying and testing a causal intervention mechanism.
  • The theory depends heavily on future validation to rise above incremental biomarker discovery.
Foundational alignment
thermodynamics · neutral (5)network theory · aligned (8)evolution · tension (4)cybernetics · aligned (7)disease etiology · tension (4)
Theory rollup
Premise plausibility7.0/10

The core premise is biologically credible: longitudinal phenotyping can capture variation in aging trajectories, and omics can reflect molecular pathways, biomarkers, and regulatory states relevant to healthspan and disease risk. The weaker part is the causal leap from cohort-associated omic patterns to mechanisms that distinguish slower aging from ordinary correlates or consequences of health status.

Explanatory power5.0/10

The theory offers a plausible discovery framework for explaining molecular differences between healthier and less healthy aging trajectories, but it does not yet explain observed evidence better than alternatives. Its explanatory power is limited because the provided context contains predictions and assumptions rather than demonstrated findings, and correlation-based omics can often be explained by non-causal biomarkers, disease burden, environment, or cohort structure.

Falsifiability7.0/10

The theory makes several testable predictions: omic signatures should correlate with longevity and healthspan, predict future age-related disease risk, and nominate mechanisms that validate experimentally or in independent cohorts. It could be weakened or falsified if well-powered longitudinal analyses fail to find reproducible predictive signatures or if nominated mechanisms fail validation. However, the theory is broad enough that negative findings in one omic layer, cohort, or disease endpoint might be dismissed rather than treated as decisive.

Ambition8.0/10

The theory targets a major unsolved aging problem: identifying molecular mechanisms that distinguish healthier or longer-lived individuals from typical aging trajectories. Its ambition is high because it aims to move from dense human longitudinal data to mechanistic discovery and disease-risk prediction. It is less than maximally ambitious because the mechanism is not highly distinctive; it is a broad systems-biology discovery strategy rather than a sharply specified causal aging theory.

Videos

This Easy Chicken Wing Recipe Will Blow Your Mind! - YouTube
moderate
0:3614,822 views106 likes6 commentsnot applicableField context

Video summary pending.

Ke Da Ke Xiao (Possibly Big Possibly Small) - Yung Ho Chang, AIA ...
moderate
41:422,269 views3 likes0 commentsnot applicableField context

Video summary pending.

Lecture 103 (Chapter 14.3)| HRK Physics | Tunnel through earth ...
low signal
49:25370 views17 likes5 commentsnot applicableField context

Video summary pending.

What to do in a car accident - Ep 1 | Meet the Changs | SBS Learn ...
moderate
4:1311,745 views125 likes0 commentsnot applicableProject specific

Video summary pending.

P.F. Chang's Chicken Lettuce Wraps - YouTube
moderate
8:0132,447 views46 commentsnot applicableField context

Video summary pending.

PF Changs Copycat Chicken Lettuce Wraps ... - YouTube
discussed
2:55436,688 views27,268 likes376 commentsnot applicableProject specific

Video summary pending.

Adaptive - P F Changs - YouTube
unwatched
1:4538 views0 likes0 commentsnot applicableProject specific

Video summary pending.

Presentation on " the changs of human live caused by covid 19 ...
unwatched
5:5313 views1 likes0 commentsnot applicableProject specific

Video summary pending.

Presentation on "The Changs of Human Life Caused by Covid 19 ...
unwatched
4:4617 views1 likes0 commentsnot applicableProject specific

Video summary pending.

PF Changs Lettuce Wraps - YouTube
moderate
0:351,964 views2 likes0 commentsunavailableProject specific

Transcript unavailable.

How to changs icons (mac) - YouTube
unwatched
3:1731 views0 likes0 commentsunavailableProject specific

Transcript unavailable.

Keto PF Changs Lettuce Wraps - YouTube
low signal
1:52109 views0 likes0 commentsunavailableProject specific

Transcript unavailable.

PF Changs / Coca-Cola
low signalneutral
1:01295 views2 likes0 commentsreadyProject specific

This video does not provide usable project-specific information about CHANGS. The available transcript content is limited to music, applause, and fragmented promotional-sounding speech, with no clear mention of the CHANGS project, healthy aging research, omics, AI bioinformatics, biomarkers, or clinical outcomes. As a result, it does not materially confirm, expand, or challenge the project brief. It should be treated as non-informative evidence for project-rating purposes.

Key takeaways
  • No discernible discussion of CHANGS appears in the transcript chunk.
  • The segment sounds promotional or advertisement-like rather than research-focused.
  • There is no usable evidence about multi-omic aging measures, organ-aging models, or volunteer/clinical data collection.
  • The video provides no support for validated biomarkers, intervention results, or clinical utility.
  • Audience reception is low signal, so even if the tone were favorable, it would still be weak evidence.
P.f Changs - YouTube
low signal
4:0983 views1 likes1 commentsunavailableProject specific

Transcript unavailable.

Date Night PF Changs West Hartford CT
low signalneutral
6:14186 views8 likes3 commentsreadyProject specific

This video does not appear to be about the CHANGS project or healthy-aging research. The available transcript content is mostly noisy, non-specific restaurant/date-night footage with no meaningful discussion of CHANGS, omics, biomarkers, clinical data, or research outputs. Nothing in the transcript supports claims about validated aging measures, organ-aging models, intervention effects, or clinical utility. As project-specific evidence, this video is effectively non-informative and should carry little to no weight in rating the project.

Key takeaways
  • No identifiable reference to CHANGS, Chulalongkorn University, BGI, or Thailand healthy-aging research.
  • The transcript is largely noise, music, and casual chatter from a restaurant/date-night setting.
  • No evidence is presented for validated biomarkers, multi-omic aging measures, organ-aging models, or intervention results.
  • The content does not function as a project promo, third-party review, or substantive discussion of the project.
  • Audience reception is low signal, so even if it had implied sentiment, it would still be weak evidence.
The Changs live at Trip Santa Monica, June 1, 2018 - full show ...
low signal
1:02:16125 views7 likes1 commentsunavailableProject specific

Transcript unavailable.

P.F. Changs CEO Damola Adamolekun says: Start your day with a conquest
moderateneutral
40:285,742 views116 likes6 commentsreadyProject specific

This video is a business leadership interview with P.F. Chang's CEO Damola Adamolekun, centered on management philosophy, sports lessons, crisis leadership, team culture, and personal discipline. Across the transcript, there is no substantive discussion of the CHANGS healthy-aging project, Chulalongkorn University, BGI, omics, biomarkers, organ-aging models, or clinical findings. The content is therefore not project-specific evidence for CHANGS' scientific progress, validation status, or utility. At most, it offers generic themes about leadership and execution that are not probative for a longevity project rating.

Key takeaways
  • The transcript is focused on restaurant leadership, culture, communication, and career development rather than longevity science.
  • No direct evidence appears about CHANGS' methods, sample collection, biomarker development, organ-aging models, interventions, or clinical utility.
  • Several chunks are overtly motivational or promotional, especially around leadership lessons and host self-promotion.
  • The speaker discusses exercise and discipline in a personal-performance sense, not as scientific evidence relevant to CHANGS.
  • Given the moderate audience reception, the video had some reach, but its relevance to CHANGS remains weak because the content is essentially unrelated.
PF Changs
low signalunfavorable
0:49802 views11 likes2 commentsreadyProject specific

This video appears to be a short promotional spot for the PF Chang's restaurant chain, not for the CHANGS healthy-aging project in Thailand. The transcript highlights restaurant branding points such as global locations, made-from-scratch kitchens, no MSG, and menu expansion into multiple Asian-inspired cuisines. It provides no discussion of Chulalongkorn University, BGI, healthy aging research, omics, AI bioinformatics, volunteer cohorts, biomarkers, or clinical outcomes. As evidence for the CHANGS project, the video is misaligned and effectively non-informative.

Key takeaways
  • The transcript is unrelated to the CHANGS longevity project and instead promotes PF Chang's restaurants.
  • It claims PF Chang's has over 300 locations worldwide.
  • It emphasizes made-from-scratch kitchens, no MSG, and high-quality ingredients.
  • It describes menu expansion beyond Chinese cuisine into other Asian-inspired offerings.
  • The video contributes no project-specific evidence about CHANGS research activity, biomarkers, interventions, or clinical utility.
Going to a parent teacher interview - Ep 7 | Meet the Changs | Learn English
moderateneutral
5:026,365 views57 likes0 commentsreadyProject specific

This video is a scripted English-learning episode about a parent-teacher interview involving the Chang family, focused on school performance, homework, and classroom behavior. The transcript teaches vocabulary such as academic progress, learning expectations, and behaviour in class through a humorous dialogue. It does not discuss the CHANGS healthy aging project, Chulalongkorn University, BGI, omics, AI bioinformatics, biomarkers, or any research outputs. As project evidence, the video is non-informative and should not affect assessment of the CHANGS aging initiative beyond noting a name coincidence.

Key takeaways
  • The content is an English-learning skit centered on a parent-teacher meeting, not a research or project video.
  • The transcript is unrelated to the CHANGS healthy aging collaboration in Thailand.
  • It provides no evidence about project execution, scientific outputs, biomarkers, interventions, or clinical utility.
  • Any apparent connection is only the shared name 'Chang/Changs,' not the longevity project itself.
  • Despite moderate audience reception, the video's relevance to the project is effectively nil.
Artist Profile:Warren Chang An Arts Are the Answer Special Presentation
low signalneutral
29:48729 views10 likes0 commentsreadyField context

This video is an artist-profile interview about painter Warren Chang, covering his upbringing, artistic influences, realist painting practice, and exhibition work. Across all chunks, the content stays focused on fine art, narrative subject matter, and Warren Chang's career rather than healthy aging, omics, AI bioinformatics, or the CHANGS project. As evidence for CHANGS, the video is effectively irrelevant and does not support claims about project outputs, biomarker validation, interventions, or clinical utility. It may offer only a name-match distraction, not meaningful field context for the project.

Key takeaways
  • The video is about artist Warren Chang's background, influences, and painting practice, not the CHANGS healthy-aging collaboration.
  • None of the chunks mention longevity research, omics, AI bioinformatics, biomarkers, clinical data, or Thailand-based institutional research.
  • The content is self-promotional and reflective in an arts-profile sense, but that tone is unrelated to evaluating CHANGS.
  • For project-rating purposes, this video provides no evidence of scientific progress, validation, intervention results, or clinical utility for CHANGS.
  • Audience reception is low signal, so even if the content had been relevant, it would still be weak evidence.

Evidence

news (15)
paper (1)
patent (101)
project page (7)
repo (1)
video (20)
web (35)
Chula Collaborates with BGI on CHANGS Research Holistic Health
Project specificfetched
https://www.facebook.com/ChulalongkornUniversity/posts/%F0%9D%98%BE%F0%9D%99%9D%F0%9D%99%AA%F0%9D%99%A1%F0%9D%99%96-%F0%9D%98%BE%F0%9D%99%A4%F0%9D%99%A1%F0%9D%99%A1%F0%9D%99%96%F0%9D%99%97%F0%9D%99%A4%F0%9D%99%A7%F0%9D%99%96%F0%9D%99%A9%F0%9D%99%9A%F0%9D%99%A8-%F0%9D%99%AC%F0%9D%99%9E%F0%9D%99%A9%F0%9D%99%9D-beijing-genomics-institute-%F0%9D%98%BD%F0%9D%99%82%F0%9D%99%84-%F0%9D%99%A4%F0%9D%99%A3-%F0%9D%98%BE%F0%9D%99%83%F0%9D%98%BC%F0%9D%99%89%F0%9D%99%82%F0%9D%99%8E-%F0%9D%99%8D%F0%9D%99%9A%F0%9D%99%A8%F0%9D%99%9A%F0%9D%99%96%F0%9D%99%A7%F0%9D%99%98%F0%9D%99%9D-%F0%9D%99%A9%F0%9D%99%A4-%F0%9D%98%BC%F0%9D%99%A3%F0%9D%99%96/1062095152621988/?locale=vi_VN
direct5/22/20264,500 chars
wiki (42)

★ AI estimate from available evidence — click any star for rationale.